Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Revenue (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Revenue for 8 consecutive years, with -$1.1 million as the latest value for Q2 2025.

  • Quarterly Revenue changed N/A to -$1.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.8 million for FY2025, N/A changed from the prior year.
  • Revenue for Q2 2025 was -$1.1 million at Crescent Biopharma, down from $75000.0 in the prior quarter.
  • The five-year high for Revenue was $1.1 million in Q1 2021, with the low at -$1.1 million in Q2 2025.
  • Average Revenue over 3 years is $26961.3, with a median of $46312.5 recorded in 2021.
  • The sharpest move saw Revenue crashed 91.34% in 2021, then surged 52716.9% in 2022.
  • Over 3 years, Revenue stood at $17625.0 in 2021, then soared by 325.53% to $75000.0 in 2022, then plummeted by 1530.67% to -$1.1 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at -$1.1 million, $75000.0, and $17625.0 for Q2 2025, Q2 2022, and Q4 2021 respectively.